HIV drug combo may shield hearts: new trial launches
NCT ID NCT07030920
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug fostemsavir to standard HIV treatment can lower the risk of heart disease in people with well-controlled HIV. Researchers will compare heart imaging and blood tests between 150 adults who get the extra drug and those who don't. Participants must be 40 or older (or have had HIV for 25+ years) and have at least one heart risk factor like smoking or high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CR CHUM
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Can a psychedelic help break meth addiction in people with HIV?
- Can a lifestyle coach lower your risk of stroke and dementia?
- Can your sleep habits shape your Heart's fate?
- Remote care may cut stroke risk — a small trial puts it to the test
- Can a phone app replace cardiac rehab? a new trial puts digital heart care to the test